Ryeqo 40 mg/1 mg/0.5 mg film-coated tablets
*Company:
Gedeon Richter IrelandStatus:
No Recent UpdateLegal Category:
Product subject to medical prescription which may not be renewed (A)Active Ingredient(s):
This medicinal product is subject to additional monitoring.
*Additional information is available within the SPC or upon request to the company
Updated on 01 February 2024
File name
Ryeqo SmPC_en_EU-1-21-1565-001-004.pdf
Reasons for updating
- Change to section 6.5 - Nature and contents of container
- Change to section 8 - Marketing authorisation number(s)
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Addition of a pack type; addition of MA numbers for the new pack type and an update to the date of revision of the text.
Updated on 01 February 2024
File name
Ryeqo PIL_en_EU-1-21-1565-001-004.pdf
Reasons for updating
- Change to section 6 - what the product looks like and pack contents
- Change to date of revision
Free text change information supplied by the pharmaceutical company
Addition of a pack type.
Updated on 01 February 2024
File name
Ryeqo SmPC_en_EU-1-21-1565-001-004.pdf
Reasons for updating
- Change to section 6.5 - Nature and contents of container
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Addition of a pack type.
Updated on 21 December 2023
File name
Ryeqo PIL_en_EU-1-21-1565-001-002.pdf
Reasons for updating
- Change to section 1 - what the product is used for
- Change to section 2 - pregnancy, breast feeding and fertility
- Change to section 3 - overdose, missed or forgotten doses
- Change to section 4 - possible side effects
- Change to section 6 - date of revision
Updated on 21 December 2023
File name
Ryeqo SmPC_en_EU-1-21-1565-001-002.pdf
Reasons for updating
- Change to section 4.1 - Therapeutic indications
- Change to section 4.2 - Posology and method of administration
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 4.8 - Undesirable effects
- Change to section 5.1 - Pharmacodynamic properties
- Change to section 5.2 - Pharmacokinetic properties
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Addition of an indication and related changes.
Updated on 04 May 2023
File name
Ryeqo_UK-IE_PIL_K-31407-1.8_march_clean.pdf
Reasons for updating
- Change to side-effects
Updated on 04 May 2023
File name
Ryeqo SmPC_en_EU-1-21-1565-001-002 IE-NI.pdf
Reasons for updating
- Change to section 4.8 - Undesirable effects
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 16 December 2022
File name
Ryeqo PIL_en_EU-1-21-1565-001-002 IE-NI.pdf
Reasons for updating
- New PIL for new product
Updated on 16 December 2022
File name
Ryeqo SmPC_en_EU-1-21-1565-001-002 IE-NI.pdf
Reasons for updating
- New SPC for new product
Legal category:Product subject to medical prescription which may not be renewed (A)